KORTUC

Tokyo, Japan· Est. 2015

KORTUC develops hydrogen peroxide-based radiosensitizers to eliminate tumor hypoxia and make radiotherapy more effective against solid cancers.

kortuc.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

KORTUC develops hydrogen peroxide-based radiosensitizers to eliminate tumor hypoxia and make radiotherapy more effective against solid cancers.

Oncology

Technology Platform

Hydrogen peroxide-based radiosensitization platform that eliminates tumor hypoxia by intratumoral injection, making cancer cells more susceptible to radiation damage.

Opportunities

Large addressable market as radiotherapy is used in ~60% of cancer patients; potential to expand into combination with emerging radiotherapy technologies like FLASH; established safety profile from extensive clinical use in Japan provides de-risking advantage.

Risk Factors

Clinical validation in controlled trials needed despite prior investigator-initiated studies; regulatory pathway for hydrogen peroxide as a drug may be challenging; competition from other radiosensitizers and hypoxia-targeting therapies; requires intratumoral injection limiting to accessible tumors.

Competitive Landscape

Competes in the radiosensitizer market with drugs like nimorazole and efaproxiral, but differentiated by direct hypoxia elimination via hydrogen peroxide and extensive clinical experience in Japan; also competes with hypoxia-activated prodrugs like evofosfamide, though with different mechanism and administration.

More companies in Japan →